Grace Frank has worked as an editor and reporter for leading American newspapers, including The New York Times, The International Herald Tribune and the Tampa Tribune. She has won numerous journalism awards, including recognition as the best education reporter in Florida (an annual honor given by the statewide teachers' union) and was nominated for a Pulitzer Prize for an investigative series into eye surgeries wrongly conducted outside a clinical trial.
Grace holds a master's degree in international relations from the University of Chicago (attending on a full-tuition fellowship), and a bachelor's degree in political science from Rutgers University–Newark campus.
The European Commission has granted orphan drug designation to viltolarsen, a treatment for people with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping, Nippon Shinyaku announced in a press release. The ... Read more
Expecting to award roughly $18 million in grants in 2020 to support research across neuromuscular diseases, the Muscular Dystrophy Association (MDA) continues to be a leader in efforts to better ... Read more
The U.S. Food and Drug Administration has placed a clinical hold on a Phase 1/2 trial testing SGT-001, a dystrophin gene therapy intended to treat Duchenne muscular dystrophy (DMD), after the ... Read more
Just days after Emflaza (deflazacort) became the first corticosteroid approved in the U.S. to treat Duchenne muscular dystrophy (DMD) regardless of mutation, the drug’s developer, Marathon Pharmaceuticals, announced it is ... Read more
Sarepta Therapeutics, Inc., announced that a U.S. Food and Drug Administration (FDA) advisory committee has been forced to postpone Friday’s scheduled hearing to review the company’s New Drug Application ... Read more